AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Trinity Biotech plc
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S67CN4
7.30▼ 0.21 (-2.81%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
—
EBITDA
Diluted EPS (TTM)
—
EBITDA Margin
Net Debt
Trading Information
Previous Close
7.51
Day's Range
7.27 – 7.80
52-Week Range
0.28 – 14.17
Volume
14.7K
Avg Volume
13.1K
Share Statistics
Shares Outstanding
Employees
401
Exchange
XNAS
Listed
1992-10-21
Share count as of December 31, 2025

Trinity Biotech plc (TRIB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Trinity Biotech plc (TRIB)
What is Trinity Biotech plc's Market Cap?
Trinity Biotech plc's Market Cap is $2.7B, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's Enterprise Value?
Trinity Biotech plc's Enterprise Value is $2.7B, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's Price / Sales?
Trinity Biotech plc's Price / Sales is 62.4×, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's EV / Revenue?
Trinity Biotech plc's EV / Revenue is 62.3×, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's EV / EBITDA?
Trinity Biotech plc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's Revenue (TTM)?
Trinity Biotech plc's Revenue (TTM) is $43.8M, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's EBITDA?
Trinity Biotech plc's EBITDA is -$15.5M, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's EBITDA Margin?
Trinity Biotech plc's EBITDA Margin is -35.5%, based on as-reported figures from SEC (XBRL) filings.
What is Trinity Biotech plc's Net Debt?
Trinity Biotech plc's Net Debt is -$4.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TRIBAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Revenues
Cost of sales
Gross profit
Other operating income/(expense)
Research and development expenses
Selling, general and administrative expenses
Selling, general and administrative expenses – Transformation costs
Once off items
Impairment charges
Operating loss
Financial income
Financial expenses
Net financing expense
Loss before tax
Total income tax (expense)/credit
Loss for the year on continuing operations
(Loss)/profit for the year on discontinued operations
Loss for the year (all attributable to owners of the parent)